Loading...
XMAD
ATRY
Market cap238mUSD
Dec 04, Last price  
2.70EUR
1D
0.00%
1Q
-4.93%
Jan 2017
82.43%
IPO
60.71%
Name

Atrys Health SA

Chart & Performance

D1W1MN
XMAD:ATRY chart
P/E
P/S
0.96
EPS
Div Yield, %
Shrs. gr., 5y
28.65%
Rev. gr., 5y
70.33%
Revenues
213m
+5.54%
1,079,2731,018,9041,089,6162,865,8864,560,7566,035,1157,294,14314,836,66731,396,438121,014,000186,994,000201,569,000212,743,000
Net income
-32m
L-30.30%
681,811336,533320,1981,294,79163,03997,15911,98500-23,197,000-23,468,000-45,590,000-31,774,000
CFO
3m
P
000409,89501,316,73301,083,49804,694,000-15,434,000-1,093,0002,997,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Atrys Health, S.A., a biomedical company, provides diagnostic services and medical treatments. The company offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics; and diagnostic second opinion, test directory, and clinical trials and R&D services. It uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology. The company also provides radiotherapy; and develops therapeutic modalities and diagnostic tools. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.
IPO date
Jul 22, 2016
Employees
1,928
Domiciled in
ES
Incorporated in
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT